Double Medical Technology Inc. (SHE:002901)
China · Delayed Price · Currency is CNY 39.31
+0.63 (1.63%)
Oct 23, 2026, 3:04 PM CST
Double Medical Technology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 15,896 | 19,261 | 12,579 | 16,805 | 14,062 | 20,310 | |
Market Cap Growth | -25.18% | 53.12% | -25.15% | 19.50% | -30.76% | -31.23% |
Enterprise Value | 14,509 | 18,309 | 11,783 | 15,847 | 12,891 | 19,519 |
Last Close Price | 39.31 | 46.75 | 30.04 | 39.17 | 32.84 | 48.14 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 22.73 | 32.12 | 35.25 | 285.02 | 151.93 | 30.17 |
Forward PE | 23.54 | 32.84 | 33.07 | 38.02 | 15.42 | 60.69 |
PS Ratio | 5.82 | 7.41 | 5.89 | 10.96 | 9.81 | 10.18 |
PB Ratio | 4.42 | 5.23 | 3.95 | 5.32 | 4.53 | 7.85 |
P/TBV Ratio | 4.77 | 5.68 | 4.36 | 5.89 | 5.05 | 8.85 |
P/FCF Ratio | 22.71 | 27.60 | 73.20 | - | - | 46.36 |
P/OCF Ratio | 18.83 | 23.17 | 28.44 | 227.43 | 109.48 | 30.17 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.31 | 7.04 | 5.52 | 10.34 | 8.99 | 9.79 |
EV/EBITDA Ratio | 18.20 | 26.29 | 26.32 | 130.66 | 110.07 | 24.96 |
EV/EBIT Ratio | 21.97 | 32.06 | 35.44 | 813.83 | 417.18 | 27.21 |
EV/FCF Ratio | 20.73 | 26.24 | 68.57 | - | - | 44.55 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.12 | 0.09 | 0.12 | 0.19 | 0.02 | 0.01 |
Debt / EBITDA Ratio | 0.53 | 0.45 | 0.84 | 4.57 | 0.55 | 0.03 |
Debt / FCF Ratio | 0.60 | 0.45 | 2.24 | - | - | 0.05 |
Net Debt / Equity Ratio | -0.41 | -0.39 | -0.27 | -0.34 | -0.41 | -0.46 |
Net Debt / EBITDA Ratio | -1.86 | -2.06 | -1.93 | -8.75 | -10.95 | -1.53 |
Net Debt / FCF Ratio | -2.09 | -2.05 | -5.02 | 4.58 | 8.19 | -2.74 |
Asset Turnover | 0.57 | 0.56 | 0.47 | 0.36 | 0.39 | 0.66 |
Inventory Turnover | 0.64 | 0.66 | 0.58 | 0.50 | 0.42 | 0.53 |
Quick Ratio | 1.88 | 2.35 | 1.59 | 1.66 | 2.35 | 2.34 |
Current Ratio | 3.02 | 3.80 | 2.99 | 2.74 | 3.80 | 3.32 |
Return on Equity (ROE) | 22.09% | 18.55% | 12.15% | 2.76% | 3.85% | 29.29% |
Return on Assets (ROA) | 8.70% | 7.64% | 4.59% | 0.28% | 0.53% | 14.90% |
Return on Invested Capital (ROIC) | 25.51% | 21.80% | 13.54% | 0.86% | 1.43% | 50.99% |
Return on Capital Employed (ROCE) | 16.70% | 14.10% | 9.60% | 0.60% | 1.00% | 27.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.40% | 3.11% | 2.84% | 0.35% | 0.66% | 3.31% |
FCF Yield | 4.40% | 3.62% | 1.37% | -1.38% | -1.11% | 2.16% |
Dividend Yield | 1.53% | 1.27% | 1.62% | 0.62% | - | 0.99% |
Payout Ratio | 1.42% | 35.75% | 33.09% | 16.00% | 226.22% | 48.14% |
Buyback Yield / Dilution | 0.35% | 1.68% | 1.49% | -0.10% | -4.35% | -0.52% |
Total Shareholder Return | 1.88% | 2.95% | 3.10% | 0.51% | -4.35% | 0.47% |